Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.

Philip S HelliwellDafna D GladmanLaura C CoatesEffie PournaraBhumik ParikhPhilip J Mease

Published in: Rheumatology and therapy (2023)

Secukinumab demonstrated efficacy vs placebo across several outcome measures in patients with oligoarticular PsA at week 12, with sustained or improved responses through week 52.

Keyphrases

juvenile idiopathic arthritis
placebo controlled
disease activity
prostate cancer
ankylosing spondylitis
double blind
rheumatoid arthritis
radical prostatectomy
systemic lupus erythematosus
randomized controlled trial
clinical trial